Insulet Corp (PODD) has emerged as a top pick among hedge funds in the medical device sector, buoyed by overwhelmingly bullish analyst ratings and a price target suggesting significant growth potential. The company's innovative tubeless insulin pump system is seen as a key driver.
Analyst Matthew O'Brien reaffirms an Overweight rating and $420 price target for Stryker, highlighting the potential of its new Mako RPS handheld orthopedic robot to capture cost-sensitive markets and compete with rivals like Zimmer Biomet.
Boston Scientific (BSX) is attracting bullish analyst attention after its strategic acquisition of Penumbra, with Truist Securities reiterating a Buy rating and a $120 price target, citing enhanced business durability and growth prospects.
DexCom Inc. (DXCM) has released preliminary Q4 figures that exceeded expectations and provided robust long-term guidance, reinforcing its position as a favored pick among analysts and hedge funds in the medical devices sector.
Despite near-term headwinds in its Nutrition segment, Abbott Laboratories (ABT) maintains a bullish long-term outlook with solid organic sales growth projected for 2026, even as major analysts adjust their price targets following Q4 results.
Wall Street analysts are raising price targets on Edwards Lifesciences, citing a renewed growth cycle driven by TAVR expansion and a strong product pipeline, positioning the medical device maker as a favored pick.
A recent physician survey on renal denervation procedure volumes has prompted analysts to adopt a more measured view of Medtronic's near-term growth potential, even as the medical device giant remains a favored long-term holding.
The world's largest payment networks are taking a measured approach to stablecoins for everyday consumer transactions, citing a lack of clear demand in developed markets and emphasizing their role as infrastructure providers rather than disruptors.
The global professional services giant reported stronger-than-expected fourth-quarter results, with revenue climbing 8.7% to $6.60 billion. Strategic investments in digital infrastructure and artificial intelligence are credited for driving growth despite headwinds in insurance pricing.
Novo Nordisk charts a bold new course, launching a pivotal oral obesity drug while restructuring its workforce and deepening its investment in next-generation cell therapies for metabolic diseases.
Sanofi announces promising late-stage results for its immunology candidate amlitelimab and expands into genetic therapies via an investment in Sensorion, signaling a strategic push into high-value therapeutic areas.
A wave of updated price targets from Wall Street analysts is prompting investors to reassess Diana Shipping Inc. The shifting forecasts reflect changing views on dry bulk shipping fundamentals and the company's strategic position, moving the stock's story beyond recent quarters.
Facing one of the longest downturns in industry history, LyondellBasell reported Q2 2025 earnings of $0.62 per share, outlining a disciplined strategy focused on cash conservation, portfolio optimization in Europe, and a pivot towards circular and low-carbon solutions to emerge stronger from the cycle.
The doughnut giant has agreed to a multimillion-dollar settlement following a 2024 cyberattack that compromised personal data of current and former staff, though it admits no fault.
From a $10 direct listing to a $150 S&P 500 constituent, Palantir's journey has been fueled by the AI boom. As government and commercial demand surge, analysts project staggering growth. But with sky-high valuations, the path forward requires navigating lofty expectations.
Insulet (PODD) shares have faced significant pressure in recent months, diverging from the company's underlying business performance. This analysis delves into whether the current price weakness presents a buying opportunity for the Omnipod maker or reflects deeper market concerns about its premium valuation and growth sustainability.
The FDA has cleared Intuitive Surgical's da Vinci 5 robotic system for select complex cardiac procedures, a move that could reshape the landscape of minimally invasive heart surgery and open a significant new market for the industry leader.
French biopharma firm Inventiva (ENXTPA:IVA) has delivered a stunning 126% total return to shareholders over the past year, sharply contrasting with losses over a three-year horizon. As the stock experiences short-term pullbacks, analysts debate whether its current €5.23 price reflects future promise or present hype, with a key drug candidate hanging in the balance.
Paramount Skydance has appointed seasoned Capitol Hill and private sector strategist Ted Lehman as its top U.S. policy executive, a move signaling an intensified government relations focus as the media giant navigates a complex merger landscape and regulatory battles.
HSBC has raised its rating on New Oriental Education & Technology Group (NYSE: EDU) from 'Hold' to 'Buy', following the company's better-than-expected Q2 FY2026 results. The upgrade highlights a robust recovery in core businesses and strategic expansion into new educational initiatives.
